Equity Profile

GSK

GSK plc

Health CarePharmaceuticals$101.4B

Apr29Wed

Pre-Earnings Brief

UpcomingQ1-2026Pre-Market9:00 AM EDT

Company Snapshot

GSK plc is a global healthcare company focused on pharmaceuticals and vaccines. With a market cap of $101 billion, GSK plays a crucial role in addressing health challenges and improving patient outcomes in the healthcare sector.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and reflects the company's ability to generate earnings for shareholders.

$1.16

Revenue

Revenue growth is essential for assessing the company's overall performance and market demand for its products.

$7.6B

Wall Street expectations, options signals, track record, and call prep available with Pro.

GSK Q1-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-32.34%

Avg Stock Reaction

-0.73%

Last Quarter Recap

In the last quarter, GSK faced challenges with earnings that fell below expectations, which raised concerns among investors. The company did not provide specific guidance for future performance.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect GSK to report earnings in line with consensus estimates, reflecting cautious optimism about its product pipeline. However, uncertainty remains due to previous earnings misses.

Bull Case

If GSK can exceed EPS and revenue expectations, it may signal a recovery in its product sales and market position, leading to positive investor sentiment.

Bear Case

Conversely, if GSK misses estimates again, it could raise further doubts about its growth strategy and ability to compete in the pharmaceutical market.

Key Metrics to Watch

Earnings Per Share (EPS)

$1.16

EPS is a key indicator of profitability and reflects the company's ability to generate earnings for shareholders.

Revenue

$7.6B

Revenue growth is essential for assessing the company's overall performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will GSK's EPS meet or exceed the consensus estimate of $1.16?

This figure is crucial for assessing the company's profitability and could influence investor confidence.

What are the key drivers behind GSK's revenue expectations of $7.6 billion?

Understanding the factors contributing to revenue growth or decline will help gauge the company's market performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate GSK's ability to recover from previous earnings misses, as the company's recent investments in R&D could yield better-than-expected results.

Supporting Evidence

Options are pricing in a larger move than historical averages, indicating heightened expectations.

GSK's recent product launches may not yet be fully reflected in analyst estimates.

Key Risk

If GSK's new products show strong market uptake, it could significantly alter revenue expectations.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it follows a pattern of previous misses, and investors are looking for signs of recovery.

Bull Confirmed If

GSK needs to report EPS of $1.16 or higher with revenue exceeding $7.6 billion to confirm a bullish outlook.

Bear Confirmed If

An EPS below $1.15 or revenue below $7.4 billion would support a bearish view.

Pre-Earnings Positioning

Options Market

Implied Move

±9.71%

Historical Avg

±2.0%

Pricing rich

The options market is pricing in a significant move, suggesting that investors anticipate volatility around the earnings report.

Options are pricing ±9.7% while GSK has averaged ±2.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

25.1%

Calls (39K)P/C Ratio: 2.84Puts (15K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 27 (48%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 27 faded and 14 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.9%, with a raw directional average of -1.9% (modestly negative historical bias).

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Mixed flows

Institutional

19.80%

of float

Insider

0.06%

of float

Holders

1,142

institutions

Top Holders· as of Dec 2025

Dodge & Cox Inc.
68,517,969 sh · $3.7B
3.38%
-12.6%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If GSK beats expectations, history suggests a potential stock increase of around 1.99%, confirming a positive turnaround.

In-Line / Cautious

An in-line report may lead to muted reactions, as investors weigh management's commentary on future growth.

Miss

A miss could result in a decline, with history indicating an average drop of 0.83% following earnings misses.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the performance of GSK's new drug launches.
2Management's commentary on cost management and operational efficiency.
3Insights into market demand for GSK's vaccines and treatments.
4Details on any regulatory approvals that could impact future sales.
5Guidance on R&D pipeline developments and their expected timelines.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Apr27

OMABReported

Grupo Aeroportuario del Centro Norte, S.A.B. de C.V.

RecapView

Apr27

PIIReported

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and reflects the company's ability to generate earnings for shareholders.

$1.16

Revenue

Revenue growth is essential for assessing the company's overall performance and market demand for its products.

$7.6B

Wall Street expectations, options signals, track record, and call prep available with Pro.

GSK Q1-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-32.34%

Avg Stock Reaction

-0.73%

Last Quarter Recap

In the last quarter, GSK faced challenges with earnings that fell below expectations, which raised concerns among investors. The company did not provide specific guidance for future performance.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect GSK to report earnings in line with consensus estimates, reflecting cautious optimism about its product pipeline. However, uncertainty remains due to previous earnings misses.

Bull Case

If GSK can exceed EPS and revenue expectations, it may signal a recovery in its product sales and market position, leading to positive investor sentiment.

Bear Case

Conversely, if GSK misses estimates again, it could raise further doubts about its growth strategy and ability to compete in the pharmaceutical market.

Key Metrics to Watch

Earnings Per Share (EPS)

$1.16

EPS is a key indicator of profitability and reflects the company's ability to generate earnings for shareholders.

Revenue

$7.6B

Revenue growth is essential for assessing the company's overall performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will GSK's EPS meet or exceed the consensus estimate of $1.16?

This figure is crucial for assessing the company's profitability and could influence investor confidence.

What are the key drivers behind GSK's revenue expectations of $7.6 billion?

Understanding the factors contributing to revenue growth or decline will help gauge the company's market performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate GSK's ability to recover from previous earnings misses, as the company's recent investments in R&D could yield better-than-expected results.

Supporting Evidence

Options are pricing in a larger move than historical averages, indicating heightened expectations.

GSK's recent product launches may not yet be fully reflected in analyst estimates.

Key Risk

If GSK's new products show strong market uptake, it could significantly alter revenue expectations.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it follows a pattern of previous misses, and investors are looking for signs of recovery.

Bull Confirmed If

GSK needs to report EPS of $1.16 or higher with revenue exceeding $7.6 billion to confirm a bullish outlook.

Bear Confirmed If

An EPS below $1.15 or revenue below $7.4 billion would support a bearish view.

Pre-Earnings Positioning

Options Market

Implied Move

±9.71%

Historical Avg

±2.0%

Pricing rich

The options market is pricing in a significant move, suggesting that investors anticipate volatility around the earnings report.

Options are pricing ±9.7% while GSK has averaged ±2.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

25.1%

Calls (39K)P/C Ratio: 2.84Puts (15K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 27 (48%)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Mixed flows

Institutional

19.80%

of float

Insider

0.06%

of float

Holders

1,142

institutions

Top Holders· as of Dec 2025

Dodge & Cox Inc.
68,517,969 sh · $3.7B
3.38%
-12.6%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If GSK beats expectations, history suggests a potential stock increase of around 1.99%, confirming a positive turnaround.

In-Line / Cautious

An in-line report may lead to muted reactions, as investors weigh management's commentary on future growth.

Miss

A miss could result in a decline, with history indicating an average drop of 0.83% following earnings misses.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the performance of GSK's new drug launches.
2Management's commentary on cost management and operational efficiency.
3Insights into market demand for GSK's vaccines and treatments.
4Details on any regulatory approvals that could impact future sales.
5Guidance on R&D pipeline developments and their expected timelines.